

**OCT 20 2005**  
**510(k) Summary**  
**for**  
**Verify® Self-Contained Biological Indicator**

**1. SPONSOR**

Albert Browne Ltd., subsidiary of STERIS Corporation  
Chancery House  
190 Waterside Road  
Hamilton Industrial Park  
Leicester LE5 1QZ  
United Kingdom

Contact: Richard Bancroft  
Telephone: 0116 276 8636

Date Prepared: October 5, 2005

**2. DEVICE NAME**

Proprietary Name: Verify® Self-Contained Biological Indicator  
Common/Usual Name: Biological indicator  
Classification Name: Biological sterilization process indicators

**3. PREDICATE DEVICE**

- Verify® Self-Contained Biological Indicator (cleared as the Assert™ Biological/Chemical Indicator, K855101)

**4. DEVICE DESCRIPTION**

The proposed Verify® Self-Contained Biological Indicator (SCBI) is identical in components, design, materials, and manufacturing specifications to the predicate Verify® Self-Contained Biological Indicator (cleared in K855101 as the Assert™ Biological/Chemical Indicator). The SCBI consists of a plastic vial that contains a disc inoculated with *Geobacillus stearothermophilus* and/or *Bacillus atrophaeus* spores and an ampoule of culture media.

The predicate device was cleared for use in 250°F (121°C) gravity steam, 270°F (132°C) gravity flash steam, 270°F (132°C) prevacuum steam, and ethylene oxide sterilization cycles. This 510(k) premarket notification was submitted to expand the indications for use for the biological indicator to include the Express abbreviated prevacuum steam sterilization cycle (see Section 5).

**5. INTENDED USE**

The Verify® Self-Contained Biological Indicator described in this 510(k) premarket notification may be used for installation testing and routine monitoring of the following steam sterilization cycle:

- 270°F (132°C), 4 min. Express abbreviated prevacuum steam sterilization cycle for packaged items

**6. PERFORMANCE TESTING**

Performance testing was conducted to validate the SCBI for use in the Express abbreviated prevacuum steam sterilization cycle. The results support the use of the SCBI for monitoring this cycle and confirms that the SCBI meets the current requirements of FDA guidance and relevant industry standards.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

OCT 20 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Albert Brown Limited  
C/O Cynthia J. M. Nolte, Ph.D., RAC  
Senior Staff Consultant  
Medical Device Consultants, Incorporated  
49 Plain Street  
North Attleboro, Massachusetts 02760

Re: K051056  
Trade/Device Name: VERIFY SELF-CONTAINED BIOLOGICAL INDICATOR  
Regulation Number: 21 CFR 880.2800  
Regulation Name: Sterilization Process Indicator  
Regulatory Class: II  
Product Code: FRC  
Dated: October 5, 2005  
Received: October 6, 2005

Dear Dr. Nolte:


We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in dark ink, appearing to read "Chiu Lin, Ph.D.", with a stylized flourish at the end.

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K051056

Device Name: Verify® Self-Contained Biological Indicator

### Indications for Use:

The Verify® Self-Contained Biological Indicator may be used for installation testing and routine monitoring of the following steam sterilization cycle:

- 270°F (132°C), 4 min. Express abbreviated prevacuum steam sterilization cycle for packaged items

Prescription Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use x  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

 10/19/05

(Division Sign-Off)  
Division of Anesthesiology, General Hospital,  
Infection Control, Dental Devices

510(k) Number: K051056